Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Kir6.1- and SUR2-dependent KATP overactivity disrupts intestinal motility in murine models of Cantú syndrome
Nathaniel W. York, Helen Parker, Zili Xie, David Tyus, Maham Akbar Waheed, Zihan Yan, Dorothy K. Grange, Maria Sara Remedi, Sarah K. England, Hongzhen Hu, Colin G. Nichols
Nathaniel W. York, Helen Parker, Zili Xie, David Tyus, Maham Akbar Waheed, Zihan Yan, Dorothy K. Grange, Maria Sara Remedi, Sarah K. England, Hongzhen Hu, Colin G. Nichols
View: Text | PDF
Research Article Gastroenterology Muscle biology

Kir6.1- and SUR2-dependent KATP overactivity disrupts intestinal motility in murine models of Cantú syndrome

  • Text
  • PDF
Abstract

Cantú syndrome (CS), caused by gain-of-function (GOF) mutations in pore-forming (Kir6.1, KCNJ8) and accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel subunit genes, is frequently accompanied by gastrointestinal (GI) dysmotility, and we describe 1 CS patient who required an implanted intestinal irrigation system for successful stooling. We used gene-modified mice to assess the underlying KATP channel subunits in gut smooth muscle and to model the consequences of altered KATP channels in CS gut. We show that Kir6.1/SUR2 subunits underlie smooth muscle KATP channels throughout the small intestine and colon. Knockin mice, carrying human KCNJ8 and ABCC9 CS mutations in the endogenous loci, exhibited reduced intrinsic contractility throughout the intestine, resulting in death when weaned onto solid food in the most severely affected animals. Death was avoided by weaning onto a liquid gel diet, implicating intestinal insufficiency and bowel impaction as the underlying cause, and GI transit was normalized by treatment with the KATP inhibitor glibenclamide. We thus define the molecular basis of intestinal KATP channel activity, the mechanism by which overactivity results in GI insufficiency, and a viable approach to therapy.

Authors

Nathaniel W. York, Helen Parker, Zili Xie, David Tyus, Maham Akbar Waheed, Zihan Yan, Dorothy K. Grange, Maria Sara Remedi, Sarah K. England, Hongzhen Hu, Colin G. Nichols

×

Figure 6

KATP GOF animals exhibit impaired transit, which can be corrected with glibenclamide.

Options: View larger image (or click on image) Download as PowerPoint
KATP GOF animals exhibit impaired transit, which can be corrected with g...
(A) Kaplan-Meier survival curves for homozygous Kir6.1VM/VM animals when weaned onto solid food. There is significant mortality around the time of weaning onto solid food (gray line), but survival is improved when weaned onto liquid diet. (B) The distribution of FITC-dextran in equal length segments of the GI tract from stomach (Sto), through the small bowel (SB), the cecum (Cec), and colon (Col) at 90 minutes following oral gavage in WT and Kir6.1WT/VM animals, with or without glibenclamide or pinacidil treatment. (C) The geometric center of FITC-dextran load from individual experiments as in B. For B and C, n = 15 for WT, n = 10 for WT + glibenclamide (Glib), n = 5 for WT + pinacidil (Pin), n = 15 for Kir6.1WT/VM, and n = 10 for Kir6.1WT/VM + Glib. Significance was determined by 1-way ANOVA and post hoc Tukey’s test for pairwise comparison. Data shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts